Huahai Pharmaceutical secures dual drug registration certificates
Zhejiang Huahai Pharmaceutical obtained drug registration certificates for Metoprolol Succinate Extended-Release Tablets and Nicardipine Hydrochloride Injection.
The Metoprolol tablets, for hypertension, angina, and chronic heart failure, required 17.04m yuan in domestic research and development. The domestic market is projected to reach 3.066bn yuan in 2024.
The Nicardipine injection, for emergency hypertension management, cost 4.98m yuan to develop. Its domestic market is estimated at 632m yuan in 2024.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Zhejiang Huahai Pharmaceutical publishes news
Free account required • Unsubscribe anytime